Nanoparticle-based drug delivery systems: An updated strategy for treating fungal keratitis
Source abstract
Abstract
Fungal keratitis is a globally blinding eye disease caused by fungi, with more than 1.05 million cases diagnosed annually, mainly in Asia. It is the most common form of infectious keratitis, accounting for approximately 40–50% of microbial keratitis cases. The disease is difficult to treat and the prognosis is often poor. Conventional antimicrobial therapies, which are the mainstay of treatment, face problems of off-target toxicity, low bioavailability, and drug-resistant fungi. In recent years, novel drug delivery systems have emerged as a promising alternative. These systems improve drug stability, extend drug residence time, control drug release, target specific tissues and cells, and reduce toxic side effects. Nanoparticle-based drug delivery systems are particularly compelling. The aim of this paper is to elucidate the mechanisms and advances of nanoparticle-based drug delivery systems in antifungal therapy and to provide new perspectives on the treatment of fungal keratitis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Ocular Infections and Treatments · Ocular Surface and Contact Lens
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Immunologic mechanism of fungal keratitis10.18240/ijo.2021.07.20 ↗
2. Eye fungal infections: a mini review10.1007/s00203-023-03536-6 ↗
3. Modern technologies in diagnosis of fungal keratitis (review)10.17691/stm2023.15.2.07 ↗
4. Novel drug delivery systems to improve the treatment of keratitis
5. Historical perspective of clinical nano and microparticle formulations for delivery of therapeutics10.1016/j.molmed.2021.04.002 ↗
6. Use of anticancer platinum compounds in combination therapies and challenges in drug delivery10.2174/0929867325666181105115849 ↗
7. Diagnostic imaging of the nasolacrimal drainage system. Part I. Radiological anatomy of lacrimal pathways. Physiology of tear secretion and tear outflow10.12659/MSM.890098 ↗
8. Editorial: genetic features contributing to eye development and disease10.3389/fcell.2022.1008907 ↗
9. Three-dimensional model of the human eye development based on computer tomograph images
10. Regulation of the ocular cell/tissue response by implantable biomaterials and drug delivery systems10.3390/bioengineering7030065 ↗
11. Biomechanics of open-globe injury: a review10.1186/s12938-023-01117-8 ↗
12. Elastic modulus and collagen organization of the rabbit cornea: epithelium to endothelium10.1016/j.actbio.2013.09.025 ↗
13. Honokiol reduces fungal load, toll-like Receptor-2, and inflammatory cytokines in aspergillus fumigatus keratitis10.1167/iovs.61.4.48 ↗
14. Outcomes of severe fungal keratitis using in vivo confocal microscopy and early therapeutic penetrating Keratoplasty10.2147/OPTH.S358709 ↗
15. The epidemiology of infectious keratitis10.1016/j.jtos.2021.08.007 ↗
16. A 5-year retrospective analysis of the risk factors, treatment, and prognosis of patients with fungal keratitis in Heilongjiang, China10.1016/j.ajo.2022.07.023 ↗
17. Ler D, Pidro A, Miokovic AP. Challenging case of treating fungal keratitis. Rom J. Ophthalmol. 2022 Jan-Mar;66(1):69–74.10.22336/rjo.2022.14 ↗
18. Fungal keratitis: mechanisms of infection and management strategies10.1016/j.survophthal.2021.08.002 ↗
19. The role of fungi in fungal keratitis10.1016/j.exer.2020.108372 ↗
20. Review of clinical and basic approaches of fungal keratitis
21. Pharmacologic therapy of mycotic keratitis10.1016/j.survophthal.2019.02.007 ↗
22. Antifungal agents: spectrum of activity, pharmacology, and clinical indications10.1016/j.idc.2015.10.012 ↗
23. Fungal keratitis: epidemiology, rapid detection, and antifungal susceptibilities of fusarium and aspergillus isolates from corneal scrapings10.1155/2019/6395840 ↗
24. Fungal keratitis in Iran: risk factors, clinical features, and mycological profile10.3389/fcimb.2023.1094182 ↗
25. Allylamines, Benzylamines, and fungal cell permeability: a review of mechanistic effects and usefulness against fungal pathogens10.3390/membranes12121171 ↗
26. Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review10.3109/21691401.2013.769446 ↗
27. Flucytosine
28. Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside10.1128/AAC.00399-19 ↗
29. Nanotechnological approaches for counteracting multidrug resistance in cancer
30. Anidulafungin versus fluconazole in the treatment of Candida albicans chorioretinitis10.1016/j.riam.2021.05.002 ↗
31. Candida keratitis and endopthalmitis after corneal transplantation; two case reports, a novel regimen and literature overview of therapeutic options10.1177/11206721211060140 ↗
32. Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: a pilot study10.4103/ijo.IJO_73_21 ↗
33. Recent perspectives in the management of fungal keratitis10.3390/jof7110907 ↗
34. In vitro antifungal susceptibility of fusarium species and aspergillus fumigatus cultured from eleven horses with fungal keratitis10.1111/vop.12995 ↗
35. Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections10.1186/s12879-024-09342-9 ↗
36. The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis10.1136/bjo.2010.191734 ↗
37. Comparison of oral voriconazole versus oral ketoconazole as an adjunct to topical natamycin in severe fungal keratitis: a randomized controlled trial10.1097/ICO.0000000000001365 ↗
38. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration10.2146/ajhp150762 ↗
39. A review of the new antifungals: posaconazole, micafungin, and anidulafungin
40. Ocular distribution of intravenously administered micafungin in rabbits10.1007/s10156-008-0612-5 ↗
41. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review10.1097/01.ico.0000154390.28254.54 ↗
42. Comparison of the ocular penetration and pharmacokinetics between natamycin and voriconazole after topical instillation in rabbits10.1089/jop.2017.0139 ↗
43. A review on applications and toxicities of metallic nanoparticles in mammalian semen biology10.1111/and.14589 ↗
44. Conductivity sensitivity of inelastic scanning tunneling microscopy10.1103/PhysRevB.32.1336 ↗
45. Gold nanoparticles perturb drug-metabolizing enzymes and antioxidants in the livers of male rats: potential impact on drug interactions10.2147/IJN.S248194 ↗
46. Construction of intelligent drug delivery system based on polysaccharide-derived polymer micelles: a review
47. Recent advancements in nanotechnology-based bacteriophage delivery strategies against bacterial ocular infections10.1016/j.micres.2023.127413 ↗
48. Systematic optimization of cationic surface engineered mucoadhesive vesicles employing Design of Experiment (DoE): a preclinical investigation10.1016/j.ijbiomac.2019.04.118 ↗
49. Nanotechnology-based strategies for treatment of ocular disease10.1016/j.apsb.2016.09.001 ↗
50. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances10.1080/1061186X.2021.1878366 ↗
51. Application of organic nanocarriers for intraocular drug delivery
52. An insight on ophthalmic drug delivery systems: focus on polymeric biomaterials-based carriers
53. Challenges in the polyene- and azole-based pharmacotherapy of ocular fungal infections10.1089/jop.2018.0089 ↗
54. Nanoparticles based therapeutic efficacy against acanthamoeba: updates and future prospect10.1016/j.exppara.2020.108008 ↗
55. Functionalized nanostructured bioactive carriers: nanoliposomes, quantum dots, tocosome, and theranostic approach10.2174/1567201819666220324092933 ↗
56. Assessment to the antifungal effects in vitro and the ocular pharmacokinetics of solid-lipid nanoparticle in rabbits10.2147/IJN.S340068 ↗
57. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
58. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective10.2174/1872211314666191224115211 ↗
59. Nanostructures for the inhibition of viral infections10.3390/molecules200814051 ↗
60. Reconstitution of TCR signaling using supported lipid bilayers10.1007/978-1-4939-6881-7_5 ↗
61. A single GUV method for revealing the action of cell-penetrating peptides in biomembranes10.1007/978-1-0716-1752-6_11 ↗
62. Update on the management of fungal keratitis10.1007/s10792-021-01873-3 ↗
63. Therapeutic contact lenses for the treatment of corneal and ocular surface diseases: advances in extended and targeted drug delivery10.1016/j.ijpharm.2023.122740 ↗
64. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B10.1093/cid/ciz076 ↗
65. Evaluation of liposomal and conventional amphotericin B in experimental fungal keratitis rabbit model10.1167/tvst.8.3.35 ↗
66. Liposomal amphotericin B (AmBisome(®)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions
67. Liposomal voriconazole (VOR) formulation for improved ocular delivery10.1016/j.colsurfb.2015.06.036 ↗
68. Rapamycin liposome gutta inhibiting fungal keratitis of rats
69. Niosome: a future of targeted drug delivery systems10.4103/0110-5558.76435 ↗
70. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies10.1080/03639045.2019.1579827 ↗
71. Targeted drug delivery in lipid-like nanocages and extracellular vesicles10.32607/20758251-2019-11-2-28-41 ↗
72. Solid lipid nanoparticles: a promising nanomaterial in drug delivery10.2174/1381612825666190903155321 ↗
73. Natamycin ocular delivery: challenges and advancements in ocular therapeutics10.1007/s12325-023-02541-x ↗
74. Niosomes: Do they increase the potency of topical natamycin ketorolac formula in treating aspergillus keratitis? An experimental study10.1089/jop.2019.0128 ↗
75. Development of sulconazole-loaded nanoemulsions for enhancement of transdermal permeation and antifungal activity10.2147/IJN.S206657 ↗
76. Gellan gum-based in situ gelling ophthalmic nanosuspension of Posaconazole10.1007/s13346-022-01155-0 ↗
77. Solid lipid nanoparticles for hydrophilic drugs10.1016/j.jconrel.2021.05.032 ↗
78. Time to overcome fluconazole resistant Candida isolates: solid lipid nanoparticles as a novel antifungal drug delivery system10.1016/j.colsurfb.2016.03.013 ↗
79. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization10.2147/IJN.S190502 ↗
80. Enhanced in vivo antifungal activity of novel cell penetrating peptide natamycin conjugate for efficient fungal keratitis management10.1016/j.ijpharm.2021.120484 ↗
81. Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme10.3390/pharmaceutics12090860 ↗
82. Nanostructured lipid carriers- A versatile carrier for Oral delivery of lipophilic drugs10.2174/1872210514666200909154959 ↗
83. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases10.1016/j.jconrel.2017.08.033 ↗
84. Thermosensitive hydrogel containing sertaconazole loaded nanostructured lipid carriers for potential treatment of fungal keratitis10.1080/10837450.2019.1616755 ↗
85. Carbon nanotubes: an emerging drug delivery carrier in cancer therapeutics10.2174/1567201817999200508092821 ↗
86. The effect of charges on the corneal penetration of solid lipid nanoparticles loaded Econazole after topical administration in rabbits10.1016/j.ejps.2023.106494 ↗
87. Effective ocular delivery of eplerenone using nanoengineered lipid carriers in rabbit model10.2147/IJN.S319814 ↗
88. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy10.1080/08982104.2016.1224899 ↗
89. Next-generation nanomedicine approaches for the management of retinal diseases10.3390/pharmaceutics15072005 ↗
90. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis10.1002/wnan.1670 ↗
91. Combination antifungal therapy: a review of current data10.14740/jocmr2992w ↗
92. In vitro activity of Carbosilane cationic dendritic molecules on prevention and treatment of Candida Albicans biofilms10.3390/pharmaceutics12100918 ↗
93. Progress of polymer-based strategies in fungal disease management: designed for different roles10.3389/fcimb.2023.1142029 ↗
94. Zero order delivery of itraconazole via polymeric micelles incorporated in situ ocular gel for the management of fungal keratitis10.1016/j.colsurfb.2015.03.059 ↗
95. Reinforcement of acrylamide hydrogels with cellulose nanocrystals using gamma radiation for antibiotic drug delivery10.3390/gels9080602 ↗
96. Recent development of functional chitosan-based hydrogels for pharmaceutical and biomedical applications10.3390/gels9040277 ↗
97. In situ forming and mucoadhesive ophthalmic voriconazole/HPβCD hydrogels for the treatment of fungal keratitis10.1016/j.ijpharm.2021.120318 ↗
98. A hydrogel-based hybrid Theranostic contact Lens for fungal keratitis10.1021/acsnano.6b00601 ↗
99. A composite system based upon hydroxypropyl cyclodextrins and soft hydrogel contact lenses for the delivery of therapeutic doses of Econazole to the cornea, in vitro10.3390/pharmaceutics14081631 ↗
100. Polymeric nanoparticle vaccines to combat emerging and pandemic threats10.1016/j.biomaterials.2020.120597 ↗